{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:52:01Z","timestamp":1792083121722,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.anai.2025.11.023","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T17:04:08Z","timestamp":1764003848000},"page":"400-408.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics and pharmacodynamics of AQST-109"],"prefix":"10.1016","volume":"136","author":[{"given":"David","family":"Golden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Greenhawt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Confer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3248-2122","authenticated-orcid":false,"given":"Carl N.","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.anai.2025.11.023_bib0001","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/ACI.0000000000000305","article-title":"Epidemiology of severe anaphylaxis: can we use population-based data to understand anaphylaxis?","volume":"16","author":"Turner","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.11.023_bib0002","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2013.08.016","article-title":"Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States","volume":"133","author":"Wood","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.11.023_bib0003","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaip.2019.11.027","article-title":"Global trends in anaphylaxis epidemiology and clinical implications","volume":"8","author":"Turner","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2025.11.023_bib0004","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis","volume":"145","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2025.11.023_bib0005","unstructured":"ARS Pharmaceuticals. neffy\u00ae (epinephrine nasal spray) prescribing information. Accessed November 11, 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/214697s000lbl.pdf"},{"key":"10.1016\/j.anai.2025.11.023_bib0006","unstructured":"ARS Pharmaceuticals. ARS Pharmaceuticals receives FDA approval of neffy\u00ae (epinephrine nasal spray), the first and only needle-free treatment for type I allergic reactions, including anaphylaxis. Accessed April 2, 2025. Available at:https:\/\/ir.ars-pharma.com\/news-releases\/news-release-details\/ars-pharmaceuticals-receives-fda-approval-neffyr-epinephrine\/"},{"key":"10.1016\/j.anai.2025.11.023_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13601-020-00326-x","article-title":"Epinephrine delivery via EpiPen\u00ae Auto-Injector or manual syringe across participants with a wide range of skin-to-muscle distances","volume":"10","author":"Worm","year":"2020","journal-title":"Clin Transl Allergy"},{"issue":"4","key":"10.1016\/j.anai.2025.11.023_bib0008","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.anai.2018.06.010","article-title":"Epinephrine auto-injector carriage and use practices among US children, adolescents, and adults","volume":"121","author":"Warren","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.11.023_bib0009","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S1081-1206(10)60056-7","article-title":"Availability of the epinephrine autoinjector at school in children with peanut allergy","volume":"100","author":"Ben-Shoshan","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2025.11.023_bib0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13223-017-0218-5","article-title":"Adherence with epinephrine autoinjector prescriptions in primary care","volume":"13","author":"Abrams","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.11.023_bib0011","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2500\/aap.2021.42.200099","article-title":"Epinephrine autoinjector prescription filling after pediatric emergency department discharge","volume":"42","author":"Cohen","year":"2021","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/j.anai.2025.11.023_bib0012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/10903127.2013.825352","article-title":"Pediatric anaphylaxis management in the prehospital setting","volume":"18","author":"Tiyyagura","year":"2014","journal-title":"Prehosp Emerg Care"},{"issue":"2","key":"10.1016\/j.anai.2025.11.023_bib0013","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.5415\/apallergy.2019.9.e12","article-title":"Carrying rates of epinephrine devices in children with food-induced anaphylaxis","volume":"9","author":"Ratanaprug","year":"2019","journal-title":"Asia Pac Allergy"},{"issue":"1","key":"10.1016\/j.anai.2025.11.023_bib0014","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jan.13818","article-title":"The fear of needles: a systematic review and meta-analysis","volume":"75","author":"McLenon","year":"2019","journal-title":"J Adv Nurs"},{"issue":"4","key":"10.1016\/j.anai.2025.11.023_bib0015","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/ACI.0b013e32833bc670","article-title":"Epinephrine and its use in anaphylaxis: current issues","volume":"10","author":"Simons","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2025.11.023_bib0016","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1208\/s12249-015-0306-0","article-title":"Sublingual diffusion of epinephrine microcrystals from rapidly disintegrating tablets for the potential first-aid treatment of anaphylaxis: in vitro and ex vivo study","volume":"16","author":"Rawas-Qalaji","year":"2015","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"10.1016\/j.anai.2025.11.023_bib0017","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.anai.2013.09.005","article-title":"Long-term stability of epinephrine sublingual tablets for the potential first-aid treatment of anaphylaxis","volume":"111","author":"Rawas-Qalaji","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.11.023_bib0018","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1067\/mai.2002.120758","article-title":"EpiPen JR versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis","volume":"109","author":"Simons","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.11.023_bib0019","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bcp.14438","article-title":"Pharmacokinetic and pharmacodynamic evidence of adrenaline administered via auto-injector for anaphylactic reactions: a review of literature","volume":"87","author":"Moss","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.anai.2025.11.023_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5607507","article-title":"Blood pressure response to submaximal exercise test in adults","volume":"2016","author":"Wielemborek-Musial","year":"2016","journal-title":"BioMed Res Int"},{"issue":"5","key":"10.1016\/j.anai.2025.11.023_bib0021","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaip.2017.06.031","article-title":"Fatal anaphylaxis: mortality rate and risk factors","volume":"5","author":"Turner","year":"2017","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625013638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625013638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:43:33Z","timestamp":1779345813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625013638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1081120625013638"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.11.023","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and pharmacodynamics of AQST-109","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}